501 related articles for article (PubMed ID: 28744329)
1. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
Flores O; Santra S; Kaittanis C; Bassiouni R; Khaled AS; Khaled AR; Grimm J; Perez JM
Theranostics; 2017; 7(9):2477-2494. PubMed ID: 28744329
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors.
Lütje S; Heskamp S; Franssen GM; Frielink C; Kip A; Hekman M; Fracasso G; Colombatti M; Herrmann K; Boerman OC; Gotthardt M; Rijpkema M
Theranostics; 2019; 9(10):2924-2938. PubMed ID: 31244933
[No Abstract] [Full Text] [Related]
3. Discovery of PSMA-specific peptide ligands for targeted drug delivery.
Jin W; Qin B; Chen Z; Liu H; Barve A; Cheng K
Int J Pharm; 2016 Nov; 513(1-2):138-147. PubMed ID: 27582001
[TBL] [Abstract][Full Text] [Related]
4.
Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
[TBL] [Abstract][Full Text] [Related]
5. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
6. Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide.
Bassiouni R; Nemec KN; Iketani A; Flores O; Showalter A; Khaled AS; Vishnubhotla P; Sprung RW; Kaittanis C; Perez JM; Khaled AR
Clin Cancer Res; 2016 Sep; 22(17):4366-79. PubMed ID: 27012814
[TBL] [Abstract][Full Text] [Related]
7. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
[TBL] [Abstract][Full Text] [Related]
8. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.
Aggarwal S; Singh P; Topaloglu O; Isaacs JT; Denmeade SR
Cancer Res; 2006 Sep; 66(18):9171-7. PubMed ID: 16982760
[TBL] [Abstract][Full Text] [Related]
9. Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes.
Li X; Yang W; Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2015 Dec; 220(Pt B):704-14. PubMed ID: 26348387
[TBL] [Abstract][Full Text] [Related]
10. Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic.
Pearce AK; Simpson JD; Fletcher NL; Houston ZH; Fuchs AV; Russell PJ; Whittaker AK; Thurecht KJ
Biomaterials; 2017 Oct; 141():330-339. PubMed ID: 28711780
[TBL] [Abstract][Full Text] [Related]
11. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
12. PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking.
Gao Y; Li Y; Li Y; Yuan L; Zhou Y; Li J; Zhao L; Zhang C; Li X; Liu Y
Nanoscale; 2015 Jan; 7(2):597-612. PubMed ID: 25419788
[TBL] [Abstract][Full Text] [Related]
13. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
Saniee F; Shabani Ravari N; Goodarzi N; Amini M; Atyabi F; Saeedian Moghadam E; Dinarvand R
Pharm Dev Technol; 2021 Apr; 26(4):381-389. PubMed ID: 33538232
[TBL] [Abstract][Full Text] [Related]
14. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
15. Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).
Patil Y; Shmeeda H; Amitay Y; Ohana P; Kumar S; Gabizon A
Nanomedicine; 2018 Jun; 14(4):1407-1416. PubMed ID: 29680672
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
18. PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.
Langut Y; Talhami A; Mamidi S; Shir A; Zigler M; Joubran S; Sagalov A; Flashner-Abramson E; Edinger N; Klein S; Levitzki A
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13655-13660. PubMed ID: 29229829
[TBL] [Abstract][Full Text] [Related]
19. Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment.
Cho HS; Dong Z; Pauletti GM; Zhang J; Xu H; Gu H; Wang L; Ewing RC; Huth C; Wang F; Shi D
ACS Nano; 2010 Sep; 4(9):5398-404. PubMed ID: 20707381
[TBL] [Abstract][Full Text] [Related]
20. The CT20 peptide causes detachment and death of metastatic breast cancer cells by promoting mitochondrial aggregation and cytoskeletal disruption.
Lee MW; Bassiouni R; Sparrow NA; Iketani A; Boohaker RJ; Moskowitz C; Vishnubhotla P; Khaled AS; Oyer J; Copik A; Fernandez-Valle C; Perez JM; Khaled AR
Cell Death Dis; 2014 May; 5(5):e1249. PubMed ID: 24853427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
